Vertex Net Receivables from 2010 to 2026
| VRTX Stock | USD 491.47 26.45 5.69% |
Net Receivables | First Reported 1999-09-30 | Previous Quarter 1.9 B | Current Value 2.1 B | Quarterly Volatility 585.4 M |
Check Vertex Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vertex Pharmaceuticals' main balance sheet or income statement drivers, such as Total Revenue of 12.6 B, Gross Profit of 10.9 B or Other Operating Expenses of 7.7 B, as well as many indicators such as Price To Sales Ratio of 9.18, Dividend Yield of 0.0 or PTB Ratio of 7.54. Vertex financial statements analysis is a perfect complement when working with Vertex Pharmaceuticals Valuation or Volatility modules.
Vertex | Net Receivables | Build AI portfolio with Vertex Stock |
The evolution of Net Receivables for Vertex Pharmaceuticals provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Vertex Pharmaceuticals compares to historical norms and industry peers.
Latest Vertex Pharmaceuticals' Net Receivables Growth Pattern
Below is the plot of the Net Receivables of Vertex Pharmaceuticals over the last few years. It is Vertex Pharmaceuticals' Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vertex Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Net Receivables | 10 Years Trend |
|
Net Receivables |
| Timeline |
Vertex Net Receivables Regression Statistics
| Arithmetic Mean | 768,036,824 | |
| Geometric Mean | 372,301,853 | |
| Coefficient Of Variation | 96.63 | |
| Mean Deviation | 643,433,204 | |
| Median | 409,688,000 | |
| Standard Deviation | 742,140,784 | |
| Sample Variance | 550772.9T | |
| Range | 2.1B | |
| R-Value | 0.94 | |
| Mean Square Error | 66311.7T | |
| R-Squared | 0.89 | |
| Slope | 138,423,299 | |
| Total Sum of Squares | 8812367.1T |
Vertex Net Receivables History
About Vertex Pharmaceuticals Financial Statements
Vertex Pharmaceuticals investors use historical fundamental indicators, such as Vertex Pharmaceuticals' Net Receivables, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Vertex Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Receivables | 2.1 B | 2.2 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Vertex Stock Analysis
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.